These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
148 related articles for article (PubMed ID: 38429922)
41. Deferiprone for the treatment of transfusional iron overload in thalassemia. Belmont A; Kwiatkowski JL Expert Rev Hematol; 2017 Jun; 10(6):493-503. PubMed ID: 28448199 [TBL] [Abstract][Full Text] [Related]
42. Long-term treatment of transfusional iron overload with the oral iron chelator deferiprone (L1): a Dutch multicenter trial. Kersten MJ; Lange R; Smeets ME; Vreugdenhil G; Roozendaal KJ; Lameijer W; Goudsmit R Ann Hematol; 1996 Nov; 73(5):247-52. PubMed ID: 8959943 [TBL] [Abstract][Full Text] [Related]
43. Desferrioxamine mesylate for managing transfusional iron overload in people with transfusion-dependent thalassaemia. Roberts DJ; Rees D; Howard J; Hyde C; Alderson P; Brunskill S Cochrane Database Syst Rev; 2005 Oct; (4):CD004450. PubMed ID: 16235363 [TBL] [Abstract][Full Text] [Related]
44. Comparison of deferiprone and deferrioxamine for the treatment of transfusional iron overload in children with beta thalassemia major. Waheed N; Ali S; Butt MA J Ayub Med Coll Abbottabad; 2014; 26(3):297-300. PubMed ID: 25671931 [TBL] [Abstract][Full Text] [Related]
45. Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia. Geneen LJ; Dorée C; Estcourt LJ Cochrane Database Syst Rev; 2023 Mar; 3(3):CD012349. PubMed ID: 36877640 [TBL] [Abstract][Full Text] [Related]
46. Transfusional iron overload and chelation therapy with deferoxamine and deferiprone (L1). Kontoghiorghes GJ; Pattichi K; Hadjigavriel M; Kolnagou A Transfus Sci; 2000 Dec; 23(3):211-23. PubMed ID: 11099897 [TBL] [Abstract][Full Text] [Related]
47. Efficacy and safety of deferasirox, an oral iron chelator, in heavily iron-overloaded patients with beta-thalassaemia: the ESCALATOR study. Taher A; El-Beshlawy A; Elalfy MS; Al Zir K; Daar S; Habr D; Kriemler-Krahn U; Hmissi A; Al Jefri A Eur J Haematol; 2009 Jun; 82(6):458-65. PubMed ID: 19187278 [TBL] [Abstract][Full Text] [Related]
48. Continuation of deferiprone therapy in patients with mild neutropenia may not lead to a more severe drop in neutrophil count. El-Beshlawy AM; El-Alfy MS; Sari TT; Chan LL; Tricta F Eur J Haematol; 2014 Apr; 92(4):337-40. PubMed ID: 24330079 [TBL] [Abstract][Full Text] [Related]
49. How I treat transfusional iron overload. Hoffbrand AV; Taher A; Cappellini MD Blood; 2012 Nov; 120(18):3657-69. PubMed ID: 22919029 [TBL] [Abstract][Full Text] [Related]
50. Efficacy and safety of early-start deferiprone in infants and young children with transfusion-dependent beta thalassemia: Evidence for iron shuttling to transferrin in a randomized, double-blind, placebo-controlled, clinical trial (START). Elalfy MS; Hamdy M; Adly A; Ebeid FSE; Temin NT; Rozova A; Lee D; Fradette C; Tricta F Am J Hematol; 2023 Sep; 98(9):1415-1424. PubMed ID: 37401738 [TBL] [Abstract][Full Text] [Related]
51. Oral chelators deferasirox and deferiprone for transfusional iron overload in thalassemia major: new data, new questions. Neufeld EJ Blood; 2006 May; 107(9):3436-41. PubMed ID: 16627763 [TBL] [Abstract][Full Text] [Related]
52. Oral deferiprone for iron chelation in people with thalassaemia. Roberts DJ; Brunskill SJ; Doree C; Williams S; Howard J; Hyde CJ Cochrane Database Syst Rev; 2007 Jul; (3):CD004839. PubMed ID: 17636775 [TBL] [Abstract][Full Text] [Related]
53. Risks associated with oral deferiprone in the treatment of infratentorial superficial siderosis. Sammaraiee Y; Banerjee G; Farmer S; Hylton B; Cowley P; Eleftheriou P; Porter J; Werring DJ J Neurol; 2020 Jan; 267(1):239-243. PubMed ID: 31620867 [TBL] [Abstract][Full Text] [Related]
54. Outcomes, utilization, and costs among thalassemia and sickle cell disease patients receiving deferoxamine therapy in the United States. Delea TE; Hagiwara M; Thomas SK; Baladi JF; Phatak PD; Coates TD Am J Hematol; 2008 Apr; 83(4):263-70. PubMed ID: 17924547 [TBL] [Abstract][Full Text] [Related]
55. Deferasirox in children with transfusion-dependent thalassemia or sickle cell anemia: A large cohort real-life experience from Turkey (REACH-THEM). Antmen B; Karakaş Z; Yeşilipek MA; Küpesiz OA; Şaşmaz İ; Uygun V; Kurtoğlu E; Oktay G; Aydogan G; Akın M; Salcioglu Z; Vergin C; Kazancı EG; Ünal S; Çalışkan Ü; Aral YZ; Türkkan E; Meral Güneş A; Tunç B; Gümrük F; Ayhan AC; Söker M; Koç A; Oymak Y; Ertem M; Timur Ç; Yıldırmak Y; İrken G; Apak H; Biner B; Eren TG; Işık Balcı Y; Koçak Ü; Karasu G; Akkaynak D; Patıroğlu T Eur J Haematol; 2019 Feb; 102(2):123-130. PubMed ID: 30300449 [TBL] [Abstract][Full Text] [Related]
56. Long-term trial of deferiprone in 51 transfusion-dependent iron overloaded patients. Hoffbrand AV; AL-Refaie F; Davis B; Siritanakatkul N; Jackson BF; Cochrane J; Prescott E; Wonke B Blood; 1998 Jan; 91(1):295-300. PubMed ID: 9414297 [TBL] [Abstract][Full Text] [Related]
57. Orally active iron chelators in the treatment of iron overload. Olivieri NF Curr Opin Hematol; 1996 Mar; 3(2):125-30. PubMed ID: 9372062 [TBL] [Abstract][Full Text] [Related]
58. A 3-year study of deferasirox therapy in sickle cell disease patients in Basra, Southern Iraq. Mohsin AM; Hassan MK Niger J Clin Pract; 2018 Jun; 21(6):735-742. PubMed ID: 29888721 [TBL] [Abstract][Full Text] [Related]
59. Comparison between deferoxamine and deferiprone (L1) in iron-loaded thalassemia patients. Taher A; Sheikh-Taha M; Koussa S; Inati A; Neeman R; Mourad F Eur J Haematol; 2001 Jul; 67(1):30-4. PubMed ID: 11553264 [TBL] [Abstract][Full Text] [Related]